NNC 45-0095
NC 45-0095 is a synthetic nonsteroidal selective estrogen receptor modulator (SERM) which was under development by Novo Nordisk for the treatment of postmenopausal osteoporosis but was never marketed.[1][2][3][4][5] It is a partial agonist of the estrogen receptor (IC50 (for binding inhibition) = 9.5 nM; EC50 = 13 nM) with mixed estrogenic and antiestrogenic activity, and shows full estrogenic activity in bone and uterus (Emax (relative to moxestrol, in Ishikawa endometrial cancer cell line) = 105%).[1][4] The compound is a pyrroloindolizine derivative.[1][2] Its development was discontinued by 2003.[5]
 | |
| Clinical data | |
|---|---|
| Other names | NNC-450095 |
| Drug class | Selective estrogen receptor modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H15NO |
| Molar mass | 261.324 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
- Jørgensen AS, Jacobsen P, Christiansen LB, Bury PS, Kanstrup A, Thorpe SM, Bain S, Naerum L, Wassermann K (February 2000). "Synthesis and pharmacology of a novel pyrrolo[2,1,5-cd] indolizine (NNC 45-0095), a high affinity non-steroidal agonist for the estrogen receptor". Bioorg. Med. Chem. Lett. 10 (4): 399–402. doi:10.1016/S0960-894X(00)00015-9. PMID 10714509.
- Sharma, Vikas; Kumar, Vipin (2014). "Indolizine: a biologically active moiety". Medicinal Chemistry Research. 23 (8): 3593–3606. doi:10.1007/s00044-014-0940-1. ISSN 1054-2523. S2CID 2643469.
- Wallace OB, Richardson TI, Dodge JA (2003). "Estrogen receptor modulators: relationships of ligand structure, receptor affinity and functional activity". Curr Top Med Chem. 3 (14): 1663–82. doi:10.2174/1568026033451727. PMID 14683521.
- Atta-ur- Rahman; Allen B. Reitz (10 December 2010). Frontiers in Medicinal Chemistry. Bentham Science Publishers. pp. 206–. ISBN 978-1-60805-205-9.
- https://adisinsight.springer.com/drugs/800014610
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.